## 3 Results
### Statistical Analysis
Table 4 represents an analysis of the ESC results obtained by patients in both hands and feet according to neurotrophic treatment (yes--1 or no--0) and triglyceride values which were divided into three groups: 0--values < 130 mg/dl, 1--values between 130 and 150 mg/dl, and 2--values greater than 150 mg/dl. In the no-treatment group, it is observed that most patients with DAN are in category 2, similar to the previous situation. As suggested by [PERSON] [48], in addition to improving glycemic control, the identification of potentially modifiable risk factors for diabetic neuropathy is of particular importance. EURODIAB identified statistically significant positive correlations between the prevalence of diabetic neuropathy and duration of diabetes, triglyceride levels, presence of hypertension, and age. In our study group, hypercholesterolemia and hypertriglyceridemia were associated with the occurrence of the condition, indicating the prevalence of mixed dyslipidemia in diabetic patients. Thus, dyslipidemia, through the factors followed (triglyceridemia and cholesterol), is a risk factor for the development of diabetic neuropathy. Figure 2 shows the distribution of ESC values according to the age of diabetes diagnosis divided into three categories: 0-5 years, 6-10 years, and more than 10 years after diagnosis. In the case of patients included in the DAN or possibly DAN categories, according to the ESC values obtained with SUDOSCAN for hands and feet, it is clear that most patients have more than 10 years since they were diagnosed with this metabolic disease. \begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline  & & & **ESC Feet** & & & **ESC Hands** & \\ \hline \multirow{4}{*}{No treatment} & \multirow{2}{*}{**Weight Status**} & \multirow{2}{*}{**NAD**} & \multirow{2}{*}{**No NAD**} & \multirow{2}{*}{**PossibleNAD**} & \multirow{2}{*}{**NAD**} & **No** & **Possible** \\  & & & & & & **NAD** & **NAD** & **NAD** \\ \hline \multirow{4}{*}{No treatment} & Normal weight & 2 & 16 & 2 & 1 & 15 & 4 \\  & Overweight & 7 & 21 & 5 & 4 & 17 & 12 \\  & Obese & 30 & 29 & 23 & 15 & 25 & 42 \\ \multirow{2}{*}{Neurotrophic treatment} & Normal weight & 1 & 1 & 0 & 1 & 1 & 0 \\  & Overweight & 1 & 10 & 1 & 2 & 6 & 4 \\ \multirow{2}{*}{Neurotrophic treatment} & Obese & 4 & 16 & 3 & 1 & 13 & 9 \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Interpretation of BMI for the ESC results obtained for feet/hands. \begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline  & & & **ESC Feet** & & & **ESC Hands** & \\ \hline \multirow{4}{*}{No treatment} & \multirow{2}{*}{**CHO \({}^{\star}\) Values**} & \multirow{2}{*}{**NAD**} & \multirow{2}{*}{**No NAD**} & \multirow{2}{*}{**PossibleNAD**} & \multirow{2}{*}{**NAD**} & **No** & **Possible** \\  & & & & & & **NAD** & **NAD** & **NAD** \\ \hline \multirow{4}{*}{No treatment} & \multirow{2}{*}{\(<\)180 mg/dl} & 1 & 31 & 5 & 5 & 23 & 9 \\  & (180, 200) mg/dl & 4 & 9 & 3 & 1 & 9 & 6 \\  & \(>\)200 mg/dl & 32 & 26 & 24 & 31 & 25 & 26 \\ \multirow{2}{*}{Neurotrophic treatment} & \multirow{2}{*}{\(<\)180 mg/dl} & 0 & 14 & 0 & 2 & 9 & 3 \\  & (180, 200) mg/dl & 1 & 3 & 0 & 1 & 3 & 0 \\ \multirow{2}{*}{Neurotrophic treatment} & \multirow{2}{*}{\(>\)200 mg/dl} & 5 & 10 & 4 & 6 & 8 & 5 \\ \hline \hline \end{tabular} \({}^{\star}\)cholesterol.  
\end{table} 
Table 3: Interpretation of cholesterol values for the ESC results obtained for feet/hands. In Table 5, we can identify notable correlations between the variables examined and susceptibility to diabetic neuropathy by interpreting the Spearman correlation values and significance level for ESC assessed for both hands and feet in the context of diabetic neuropathy risk. Thus, statistically significant and negative correlations are observed between ESC values for both hands and feet and values for neurological risk. The correlation coefficient \(-0.89\) indicates a strong negative correlation and that, as ESC decreases, the risk of diabetic neuropathy increases considerably.